Skip to main content
SpringerLink
Log in

Terapia medica integrata nei carcinomi squamocellulari

  • Chapter
Tumori della testa e del collo

  • 905 Accesses

Riassunto

Tradizionalmente la chirurgia, associata o meno alla radioterapia, ha rappresentato il trattamento considera o standard nella storia della terapia dei tumori squamocellulari del distretto cervico-facciale. L’integrazione di questi trattamenti con la terapia medica, intendendo con questa definizione sia la chemioterapia sia i nuovi farmaci, i cosiddetti farmaci biologici, ha un’origine piuttosto recente.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 119.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 139.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Bibliografia

  1. Bonner JA, Harari PM, Giralt J et al (2006) Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354:567–578

    Article  PubMed  CAS  Google Scholar 

  2. Pignon JP, Bourhis J, Domenge C et al (2000) Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet 355:949–955

    CAS  Google Scholar 

  3. Pignon JP, le Maitre A, Maillard E et al (2009) Metaanalysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol 92:4–14

    Article  PubMed  Google Scholar 

  4. Forastiere AA, Goepfert H, Maor M et al (2003) Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 349:2091–2098

    Article  PubMed  CAS  Google Scholar 

  5. Paccagnella A, Orlando A, Marchiori C et al (1994) Phase III trial of initial chemotherapy in stage III or IV head and neck cancers: a study by the Gruppo di Studio sui Tumori della Testae del Collo. J Natl Cancer Inst 86:265–272

    Article  PubMed  CAS  Google Scholar 

  6. Zorat PL, Paccagnella A, Cavaniglia G et al (2004) Randomized phase III trial of neoadjuvant chemotherapy in head and neck cancer: 10-year follow-up. J Natl Cancer Inst 96:1714–1717

    Article  PubMed  CAS  Google Scholar 

  7. Domenge C, Hill C, Lefebvre JL, De Raucourt D et al (2000) Randomized trial of neoadjuvant chemotherapy in oropharyngeal carcinoma. French Groupe d’Etude des Tumeurs de la Téte et du Cou (GETTEC) Br J Cancer 83:1594–1598

    CAS  Google Scholar 

  8. Forastiere AA (1991) Randomized trials of induction chemotherapy. A entical review. Hematol Oncol Clin North Am 5:725–736

    CAS  Google Scholar 

  9. Hitt R, López-Pousa A, Martínez-Trufero J et al (2005) Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer. J Clin Oncol 23:8636–8645

    Article  PubMed  Google Scholar 

  10. Vermorken JB, Remenar E, van Herpen C et al (2007) Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med 357:1695–1704

    Article  PubMed  CAS  Google Scholar 

  11. Posner MR, Hershock DM, Blajman CR et al (2007) Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 357:1705–1715

    Article  PubMed  CAS  Google Scholar 

  12. Paccagnella A, Ghi MG, Loreggian L et al (2009) Concomitant chemoradiotherapy versus induction docetaxel, cisplatin and 5-fluorouracil (TPF) followed by concomitant chemoradiotherapy in locally advanced head and neck cancer: a phase II randomized study. Ann Oncol, 21:1515–1522

    Article  PubMed  Google Scholar 

  13. Haddad RI, Tishler RB, Norris C et al (2009) Phase I study of C-TPF in patients with locally advanced squamous cell carcinoma of the head and neck J Clin Oncol 27:4448–4453

    Article  PubMed  CAS  Google Scholar 

  14. R. Mesia S, Vázquez JJ, Grau JA et al (2009) A single-arm phase II trial to evaluate the combination of cetuximab plus docetaxel, cisplatin, and 5-fluorouracil (TPF) as induction chemotherapy (IC) in patients (pts) with unresectable SCCHN Journal of Clinical Oncology, ASCO Annual Meeting Proceedings (Post-Meeting Edition) 2009:6015

    Google Scholar 

  15. The Department of Veterans Affairs Laryngeal Cancer Study Group (1991) Induction Chemotherapy Plus Radiation Compared with Surgery Plus Radiation in Patients with Advanced Laryngeal Cancer. N Eng J Med 324:1685–1690

    Article  Google Scholar 

  16. Lefebvre JL, Chevalier D, Luboinski B et al (1996) Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer phase III trial. EORTC Head and Neck Cancer Cooperative Group. J Natl Cancer Inst 88:890–899

    CAS  Google Scholar 

  17. Richard JM, Sancho-Garnier H, Pessey JJ et al (1998) Randomized trial of induction chemotherapy in larynx carcinoma. Oral Oncol 34:224–228

    Article  PubMed  CAS  Google Scholar 

  18. Spaulding MB, Fischer SG, Wolf GT (1994) Tumor Response, Toxicity, and Survival After Neoadjuvant Organ-Preserving Chemotherapy for Advanced Laryngeal Carcinoma. J Clin Oncol 12:1592–1599

    PubMed  CAS  Google Scholar 

  19. Bonner J, Harari P, Giralt J et al (2005) Improved preservation of the larynx with the addition of cetuximab to radiation for cancers of the larynx and hypopharynx. J Clin Oncol, Annual Meeting Proceedings. Abs. 5533

    Google Scholar 

  20. Pointreau Y, Garaud P, Chapet S et al (2009) Randomized trial of induction chemotherapy with cisplatin and 5-fluorouracil with or without docetaxel for larynx preservation. J Natl Cancer Inst 101:498–506

    Article  PubMed  CAS  Google Scholar 

  21. Lefebvre JL, Rolland F, Tesselaar M et al (2009) Phase 3 randomized trial on larynx preservation comparing sequential vs alternating chemotherapy and radiotherapy. J Natl Cancer Inst 101:142–152

    Article  PubMed  CAS  Google Scholar 

  22. Posner MR, Norris CM, Wirth LJ et al (2009) Sequential therapy for the locally advanced larynx and hypopharynx cancer subgroup in TAX 324: survival, surgery, and organ preservation. Ann Oncol 20:921–927

    Article  PubMed  CAS  Google Scholar 

  23. Lefebvre JL, Pointreau Y, Rolland F et al (2011) Sequential chemoradiotherapy (SCRT) for larynx preservation (LP): Preliminary results of the randomized phase II TREM-PLIN study. J Clin Oncol (suppl; abstr. 5501)

    Google Scholar 

  24. Forastiere AA, Maor M, Weber RS et al (2006) Long term results of intergroup RTOG 91-11: a phase III trial to preserve the larynx-induction cisplatin/5-FU and radiotherapy therapy versus concurrent cisplatin and radiotherapy therapy versus radiotherapy therapy. J Clin Oncol 24:5517

    Article  Google Scholar 

  25. Lefebvre JL, Ang KK Larynx preservation Consensus Panel (2009) Larynx preservation clinical trial design: key issues and recommendations-a consensus panel summary. Int J Radiat Oncol Biol Phys 73:1293–1303

    Article  PubMed  Google Scholar 

  26. Bernier J, Domenge C, Ozsahin M et al (2004) Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 350:1945–1952

    Article  PubMed  CAS  Google Scholar 

  27. Merlano M, Benasso M, Corvo R et al (1996) Five-year update of a randomized trial of alternating radiotherapy and chemotherapy compared with radiotherapy alone in treatment of unresectable squamous cell carcinoma of the head and neck. J Natl Cancer Inst 88:583–589

    Article  PubMed  CAS  Google Scholar 

  28. Adelstein DJ, Lavertu P, Saxton JP et al (2000) Mature results of a phase III randomized trial comparing concurrent chemoradiotherapy with radiation therapy alone in patients with stage III and IV squamous cell carcinoma of the head and neck. Cancer 88:876–883

    Article  PubMed  CAS  Google Scholar 

  29. Adelstein DJ, Li Y, Adams GL et al (2003) An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol 21:92–98

    Article  PubMed  Google Scholar 

  30. Jeremic B, Shibamoto Y, Milicic B et al (2000) Hyperfractionated radiation therapy with or without concurrent lowdose daily cisplatin in locally advanced squamous cell carcinoma of the head and neck: a prospective randomized trial. J Clin Oncol 18:1458–1464

    PubMed  CAS  Google Scholar 

  31. Wendt TG, Grabenbauer GG, Rodel CM et al (1998) Simultaneous radiochemotherapy versus radiotherapy alone in advanced head and neck cancer: a randomized multicenter study. J Clin Oncol 16:1318–1324

    PubMed  CAS  Google Scholar 

  32. Bensadoun RJ, Bénézery K, Dassonville O et al (2006) French multicenter phase III randomized study testing concurrent twice-a-day radiotherapy and cisplatin/5-fluorouracil chemotherapy (BiRCF) in unresectable pharyngeal carcinoma: Results at 2 years (FNCLCC-GORTEC). Int J Radiat Oncol Biol Phys 64:983–994

    Article  PubMed  CAS  Google Scholar 

  33. Brizel DM, Murphy BA, Rosenthal DI et al (2008) Phase II study of palifermin and concurrent chemoradiation in head and neck squamous cell carcinoma J Clin Oncol 26:2489–2496

    Article  PubMed  CAS  Google Scholar 

  34. Calais G, Alfonsi M, Bardet E et al (1999) Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma. J Natl Cancer Inst 91:2081–2086

    Article  PubMed  CAS  Google Scholar 

  35. Denis F, Garaud P, Bardet E et al (2004) Final results of the 94-01 French Head and Neck Oncology and Radiotherapy Group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced-stage oropharynx carcinoma J Clin Oncol 22:69–76

    Article  PubMed  Google Scholar 

  36. Budach V, Stuschke M, Budach W et al (2005) Hyperfractionated accelerated chemoradiation with concurrent fluorouracil-mitomycin is more effective than dose-escalated hyperfractionated accelerated radiation therapy alone in locally advanced head and neck cancer: final results of the radiotherapy cooperative clinical trials group of the German Cancer Society 95-06 Prospective Randomized Trial. J Clin Oncol 23:1125–1135

    Article  PubMed  CAS  Google Scholar 

  37. Fountzilas G, Ciuleanu E, Dafni U et al (2004) Concomitant radiochemotherapy vs radiotherapy alone in patients with head and neck cancer: a Hellenic Cooperative Oncology Group Phase III Study. Med Oncol 21:95–107

    Article  PubMed  Google Scholar 

  38. Cooper JS, Pajak TF, Forastiere AA et al (2004) Postoperative concurrent radiotherapy and chemotherapy for highrisk squamous-cell carcinoma of the head and neck? Engl J Med 350:1937–1944

    Article  Google Scholar 

  39. Bourhis J, Overgaard J, Audry H et al (2006) Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis. Lancet 368:843–854

    Article  PubMed  Google Scholar 

  40. Bachaud JM, Cohen-Jonathan E, Alzieu C et al (1996) Combined postoperative radiotherapy and weekly cisplatin infusion for locally advanced head and neck carcinoma: final report of a randomized trial. Int J Radiat Oncol Biol Phys 36:999–1004

    Article  PubMed  CAS  Google Scholar 

  41. Huguenin P, Beer KT, Allai A et al (2004) Concomitant cisplatin significantly improves locoregional control in advanced head and neck cancers treated with hyperfractionated radiotherapy. J Clin Oncol 22:4665–4673

    Article  PubMed  CAS  Google Scholar 

  42. Granata R, Pond G, Kim J et al (2009) Cisplatin dose intensity correlates with outcome in patients with locally advanced head and neck squamous cell carcinoma receiving concurrent cisplatin based chemoradiation: a multiinstitutional experience. Eur J Cancer 7:472 Abs 8506

    Google Scholar 

  43. Adelstein DJ, Saxton JP, Lavertu P et al (1997) A phase III randomized trial comparing concurrent chemotherapy and radiotherapy with radiotherapy alone in resectable stage III and IV squamous cell head and neck cancer: preliminary results. Head Neck 19:567–575

    Article  PubMed  CAS  Google Scholar 

  44. Trotti A, Bellm LA, Epstein JB et al (2003) Mucositis incidence, severity and associated outcomes in patients with head and neck cancer receiving radiotherapy with or without chemotherapy: a systematic literature review. Radiother Oncol 66:253–262

    Article  PubMed  Google Scholar 

  45. Machtay M, Moughan J, Trotti A et al (2008) Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head & neck cancer: a RTOG analysis. J Clin Oncol 26:3582–3589

    Article  PubMed  CAS  Google Scholar 

  46. Bucci MK, Bevan A, Roach M (2003) 3rd Advances in radiation therapy: conventional to 3D, to IMRT, to 4D, and beyond Cancer J Clin 55:117–134

    Article  Google Scholar 

  47. Feng FY, Kim HM, Lyden TH et al (2007) Intensity-modulated radiotherapy of head and neck cancer aiming to reduce dysphagia: early dose-effect relationships for the swallowing structures. Int J Radiat Oncol Biol Phys 68:1289–1298

    Article  PubMed  Google Scholar 

  48. Kouvaris JR, Kouloulias VE, Vlahos LJ (2007) Amifostine: the first selective-target and broad-spectrum radioprotector. Oncologist 12:738–747

    Article  PubMed  CAS  Google Scholar 

  49. Bonner JA, Harari PM, Giralt J et al (2010) Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 111:21–28

    Article  Google Scholar 

  50. Chung CH, Ely K, McGavran L et al (2006) Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas. J Clin Oncol 24:4170–4176

    Article  PubMed  CAS  Google Scholar 

  51. Bissada E, Abou-Chacra Z, Weng X et al (2008) Prevalence of K-RAS codon 12 mutations in locally advanced head and neck squamous cell carcinoma and influence with regards to response to chemoradiation therapy. Journal of Clinical Oncology, ASCO Annual Meeting Proceedings (Post-Meeting Edition) 26:15:17005

    Google Scholar 

  52. Licitra L, Mesia R, Rivera F et al (2011) Evaluation of EGFR gene copy number as a predictive biomarker for the efficacy of cetuximab in combination with chemotherapy in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck: EXTREME study. Ann Oncol 22:1078–1087

    Article  PubMed  CAS  Google Scholar 

  53. Benasso M, Lionetto R, Corvo R et al (2003) Impact of the treating institution on the survival of patients with head and neck cancer treated with concomitant alternating chemotherapy and radiation. Eur J Cancer 39:1895–1898

    Article  PubMed  CAS  Google Scholar 

  54. Cook JA, Jones AS, Phillips DE, Soler Lluch E (1993) Implications of tumour in resection margins following surgical treatment of squamous cell carcinoma of the head and neck. Clin Otolaryngol Allied Sci 18:37–41

    Article  PubMed  CAS  Google Scholar 

  55. Jones AS, Bin Hanafi Z, Nadapalan V et al (1996) Do positive resection margins after ablative surgery for head and neck cancer adversely affect prognosis? A study of 352 patients with recurrent carcinoma following radiotherapy treated by salvage surgery. Br J Cancer 74:128–132

    Article  PubMed  CAS  Google Scholar 

  56. Huang D, Johnson CR, Schmidt-Ullrich RK et al (1992) Incompletely resected advanced squamous cell carcinoma of the head and neck: the effectiveness of adjuvant vs. salvage radiotherapy. Radiother Oncol 24:87–93

    Article  PubMed  CAS  Google Scholar 

  57. Hicks WL Jr, Loree TR, Garcia RI et al (1997) Squamous cell carcinoma of the floor of mouth: a 20-year review. Head Neck 19:400–405

    Article  PubMed  Google Scholar 

  58. Loree TR, Strong EW (1990) Significance of positive margins in oral cavity squamous carcinoma. Am J Surg 160:410–414

    Article  PubMed  CAS  Google Scholar 

  59. Woolgar JA, Rogers S, West CR et al (1999) Survival and patterns of recurrence in 200 oral cancer patients treated by radical surgery and neck dissection. Oral Oncol 35:257–265

    Article  PubMed  CAS  Google Scholar 

  60. Laramore GE, Scott CB, al-Sairaf M et al (1992) Adjuvant chemotherapy for resectable squamous cell carcinomas of the head and neck: report on Intergroup Study 0034. Int J Radiat Oncol Biol Phys 23:705–713

    Article  PubMed  CAS  Google Scholar 

  61. Bernier J, Cooper JS, Pajak TF et al (2005) Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931 ) and RTOG (# 9501). Head Neck 27:843–850

    Article  PubMed  Google Scholar 

  62. Forastiere A, Koch W, Troth A et al (2001) Head and neck cancer. N Engl J Med 345:1890–1900

    Article  PubMed  CAS  Google Scholar 

  63. Forastiere AA, Metch B, Schuller DE et al (1992) Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study. J Clin Oncol 10:1245–1251

    PubMed  CAS  Google Scholar 

  64. Jacobs C, Lyman G, Velez-García E et al (1992) A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. J Clin Oncol 10:257–263

    PubMed  CAS  Google Scholar 

  65. Spector JG, Sessions DG, Haughey BH et al (2001) Delayed regional metastases, distant metastases, and second primary malignancies in squamous cell carcinomas of the larynx and hypopharynx. Laryngoscope 111:1079–1087

    Article  PubMed  CAS  Google Scholar 

  66. Garavello W, Ciardo A, Spreafico R et al (2006) Risk factors for distant metastases in head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 132:762–766

    Article  PubMed  Google Scholar 

  67. Parsons JT, Mendenhall WM, Stringer SP et al (1997) An analysis of factors influencing the outcome of postoperative irradiation for squamous cell carcinoma of the oral cavity. Int J Radiat Oncol Biol Phys 39:137–148

    PubMed  CAS  Google Scholar 

  68. Argiris A, Li Y, Forastiere A (2004) Prognostic factors and long-term survivorship in patients with recurrent or metastatic carcinoma of the head and neck Cancer 101:2222–2229

    Article  PubMed  Google Scholar 

  69. No authors listed (1990) A phase III randomised trial of cisplatinum, methotrextate, cisplatinum + methotrexate and cisplatinum + 5-FU in end stage squamous carcinoma of the head and neck. Liverpool Head and Neck Oncology Group. Br J Cancer 61:311–315

    Google Scholar 

  70. Clavel M, Vermorken JB, Cognetti F et al (1994) Randomized comparison of cisplatin, methotrexate, bleomycin and vincristine (CABO) versus cisplatin and 5-fluorouracil (CF) versus cisplatin (C) in recurrent or metastatic squamous cell carcinoma of the head and neck. A phase III study of the EORTC Head and Neck Cancer Cooperative Group. Ann Oncol 5:521–526

    CAS  Google Scholar 

  71. Vermorken JB, Catimel G, De Mulder P et al (1999) Randomized phase II trial of weekly methotrexate versus two schedules of three-weekly paclitaxel (Taxol®) in patients with metastatic or recurrent squamous cell carcinoma of the head and neck. Proc Am Soc Clin Oncol 18:395a

    Google Scholar 

  72. Forastiere AA, Leong T, Rowinsky E et al (2001) Phase III comparison of high-dose paclitaxel + cisplatin + granulocyte colony-stimulating factor versus low-dose paclitaxel + cisplatin in advanced head and neck cancer: Eastern Cooperative Oncology Group Study El393. J Clin Oncol 19:1088–1095

    PubMed  CAS  Google Scholar 

  73. Gibson MK, Li Y, Murphy B et al (2005). Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (El395): an intergroup trial of the Eastern Cooperative Oncology Group. J Clin Oncol 23:3562–3567

    Article  PubMed  CAS  Google Scholar 

  74. Vermorken JB, Mesia R, Rivera F et al (2008) Platinumbased chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 359:1116–1127

    Article  PubMed  CAS  Google Scholar 

  75. Vermorken JB, Stöhlmacher J, Davidenko I et al (2010) Primary efficacy and safety results of spectrum, a phase 3 trial in patients (pts) with recurrent and/or metastatic (r/m) squamous cell carcinoma of the head and neck (SCHNC) receiving chemotherapy with or without panitumumab (PMAB). Ann Oncol 21: Abs LBA 26

    Google Scholar 

  76. Urba S, van Herpen CM, Sahoo TP et al (2010) Phase III study of pemetrexed in combination with cisplatin (PEM/CIS) versus placebo plus cisplatin (CIS) in patients with recurrent or metastatic squamous cell head and neck cancer (HNC). Ann Oncol 2: Abstract 10030

    Google Scholar 

  77. Leon X, Hitt R, Constenla M et al (2005) A retrospective analysis of the outcome of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck refractory to a platinum-based chemotherapy. Clin Oncol (R Coll Radiol) 17:418–424

    Article  CAS  Google Scholar 

  78. Forastiere AA, Shank D, Neuberg D et al (1998) Final report of a phase II evaluation of paclitaxel in patients with advanced squamous cell carcinoma of the head and neck: an Eastern Cooperative Oncology Group trial (PA390). Cancer 82:2270–2274

    Article  PubMed  CAS  Google Scholar 

  79. Guardiola E, Peyrade F, Chaigneau L et al (2004) Results of a randomised phase II study comparing decetaxel with methotrexate in patients with recurrent head and neck cancer. Eur J Cancer 40:2071–2076

    Article  PubMed  CAS  Google Scholar 

  80. Stewart JS, Cohen EE, Licitra L et al (2009) Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck. J Clin Oncol 27:1864–1871

    Article  PubMed  CAS  Google Scholar 

  81. Specenier PM, Vermorken JB (2008) Recurrent head and neck cancer: current treatment and future prospects. Expert Rev Anticancer Ther 8:375–391

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Dipartimento di Oncologia Medica, S.S. Trattamento Medico dei Tumori Testa-Collo, Fondazione IRCSS Istituto Nazionale del Tumori, Milano, Italia

    Laura D. Locati

Authors
  1. Laura D. Locati
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Marco Merlano
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2011 Springer-Verlag Italia

About this chapter

Cite this chapter

Locati, L.D., Merlano, M. (2011). Terapia medica integrata nei carcinomi squamocellulari. In: Tumori della testa e del collo. Springer, Milano. https://doi.org/10.1007/978-88-470-1806-8_14

Download citation

  • DOI: https://doi.org/10.1007/978-88-470-1806-8_14

  • Publisher Name: Springer, Milano

  • Print ISBN: 978-88-470-1805-1

  • Online ISBN: 978-88-470-1806-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation